Medgenics (MDGN) Misses Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Medgenics Reports First Quarter 2016 Financial Results and NFC-1 Program Update
May 10, 2016 8:04 AM EDTPHILADELPHIA, PA -- (Marketwired) -- 05/10/16 -- Medgenics, Inc. (NYSE MKT: MDGN)
Rapid enrollment in phenotype/genotype study of mGluR positive ADHD patients Data support the prevalence of mGluR mutation in broad ADHD population Enrollment to begin in Phase 2/3 clinical trial in mGluR+ ADHD patients Enrollment to begin in Phase 1/2 clinical trial in 22q Deletion Syndrome patientsMedgenics, Inc. (NYSE MKT: MDGN) (the Company) today announced first... More
